Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1980 Apr;56(654):229–233. doi: 10.1136/pgmj.56.654.229

Some cardiovascular problems with disopyramide.

S J Warrington, J Hamer
PMCID: PMC2425888  PMID: 7433320

Abstract

Five patients with apparent adverse cardiovascular effects of disopyramide are reveiwed. Attention is drawn to the following problems. (1) A vagolytic effect may produce a sinus tachycardia with wide QRS complexes due to aberrant conduction or intraventricular block superficially resembling a ventricular tachycardia, or may allow increased transmission of an atrial tachycardia or atrial flutter to the ventricles by improving atrio-ventricular conduction. (2) Although the vagolytic effect is helpful in increasing sinus rate in patients with sinus node disease, disopyramide may lead to bradycardia and asytolic cardiac arrest, and should not be used without a demand pacemaker. (3) Dangerous ventricular arrhythmias may be provoked in susceptible subjects, as with quinidine. (4) Rapid intravenous injection may produce transient toxic effects before the drug is distributed. The rate of injection as a loading dose for prophylaxis should be slower (2 mg/kg in 15 min) than for the urgent conversion of a resistent tachycardia (2 mg/kg in 5 min). Although disopyramide seems less toxic than quinidine, caution is advised, as over-enthusiastic application of disopyramide, particularly with rapid intravenous injection, might tend to bring a useful new agent into disrepute.

Full text

PDF
229

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Casedevant B., Sabaut D., Clementy J., Dallocchio M. Syncopes par torsades de pointes en rapport avec la prise de disopyramide. Nouv Presse Med. 1975 Oct 4;4(32):2339–2339. [PubMed] [Google Scholar]
  2. Danilo P., Jr, Rosen M. R. Cardiac effects of disopyramide. Am Heart J. 1976 Oct;92(4):532–536. doi: 10.1016/s0002-8703(76)80054-3. [DOI] [PubMed] [Google Scholar]
  3. Desruelles J., Gerard A., Ducatillon P., Herbaux A. Nos premiers essais cliniques du disopyramide (H 3292) dans les troubles du rythme cardiaque. Therapie. 1967 Jul-Aug;22(4):937–944. [PubMed] [Google Scholar]
  4. Hayler A. M., Holt D. W., Volans G. N. Fatal overdosage with disopyramide. Lancet. 1978 May 6;1(8071):968–969. doi: 10.1016/s0140-6736(78)90253-2. [DOI] [PubMed] [Google Scholar]
  5. Kidner P. H. Prevention of ventricular arrhythmias after myocardial infarction. J R Coll Physicians Lond. 1977 Jul;11(4):352–362. [PMC free article] [PubMed] [Google Scholar]
  6. Krikler D. M., Curry P. V. Torsade De Pointes, an atypical ventricular tachycardia. Br Heart J. 1976 Feb;38(2):117–120. doi: 10.1136/hrt.38.2.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Markiewicz W., Winkle R., Binetti G., Kernoff R., Harrison D. C. Normal myocardial contractile state in the presence of quinidine. Circulation. 1976 Jan;53(1):101–106. doi: 10.1161/01.cir.53.1.101. [DOI] [PubMed] [Google Scholar]
  8. Mason J. W., Winkle R. A., Ingels N. B., Daughters G. T., Harrison D. C., Stinson E. B. Hemodynamic effects of intravenously administered quinidine on the transplanted human heart. Am J Cardiol. 1977 Jul;40(1):99–104. doi: 10.1016/0002-9149(77)90107-2. [DOI] [PubMed] [Google Scholar]
  9. Rangno R. E., Warnica W., Ogilvie R. I., Kreeft J., Bridger E. Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia. J Int Med Res. 1976;4(1 Suppl):54–58. [PubMed] [Google Scholar]
  10. Ranney R. E., Dean R. R., Karim A., Radzialowski F. M. Disopyramide phosphate: pharmacokinetic and pharmacologic relationships of a new antiarrhythmic agent. Arch Int Pharmacodyn Ther. 1971 May;191(1):162–188. [PubMed] [Google Scholar]
  11. Ross D., Vohra J., Sloman J. G. Disopyramide in myocardial infarction. Lancet. 1978 Feb 11;1(8059):330–330. doi: 10.1016/s0140-6736(78)90103-4. [DOI] [PubMed] [Google Scholar]
  12. Seipel L., Breithardt G. Letter: Sinus recovery time after disopyramide phosphate. Am J Cardiol. 1976 Jun;37(7):1118–1119. doi: 10.1016/0002-9149(76)90447-1. [DOI] [PubMed] [Google Scholar]
  13. Siklos P., Chalmers T. M., Evans D. W. Ventricular tachycardia after disopyramide. Lancet. 1978 Jan 14;1(8055):98–99. doi: 10.1016/s0140-6736(78)90038-7. [DOI] [PubMed] [Google Scholar]
  14. Vismara L. A., Mason D. T., Amsterdam E. A. Disopyramide phosphate: clinical efficacy of a new oral antiarrhythmic drug. Clin Pharmacol Ther. 1974 Aug;16(2):330–335. doi: 10.1002/cpt1974162330. [DOI] [PubMed] [Google Scholar]
  15. Vismara L. A., Vera Z., Miller R. R., Mason D. T. Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia. Am J Cardiol. 1977 Jun;39(7):1027–1034. doi: 10.1016/s0002-9149(77)80218-x. [DOI] [PubMed] [Google Scholar]
  16. Zainal N., Carmichael D. J., Griffiths J. W., Besterman E. M., Kidner P. H., Gillham A. D., Summers G. D. Oral disopyramide for the prevention of arrhythmias in patients with acute myocardial infarction admitted to open wards. Lancet. 1977 Oct 29;2(8044):887–889. doi: 10.1016/s0140-6736(77)90829-7. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES